Welcome to our dedicated page for Beam Therapeutics SEC filings (Ticker: BEAM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Beam Therapeutics Inc. filings document the regulatory record for a Nasdaq-listed biotechnology company developing base-editing genetic medicines. Its Form 8-K reports cover operating results, portfolio updates, senior secured credit facility terms, license and standby license arrangements for base-editing patent rights, board changes and Regulation FD presentations.
Proxy materials describe annual meeting matters, director elections, executive compensation, equity awards and stockholder voting procedures. The filings also identify Beam’s common stock, capital structure, material agreements and governance practices tied to its clinical-stage biotechnology business.
Beam Therapeutics Inc. reports Q1 2026 results with license and collaboration revenue of $31.7 million, up from $7.5 million a year earlier, narrowing operating loss. Research and development spending reached $104.5 million, while net loss improved to $94.3 million, or $0.91 per share.
Beam ended the quarter with $1.2 billion in cash, cash equivalents and marketable securities and drew an initial $100 million from a new credit facility maturing in 2033. Management believes this liquidity can fund operations for at least 12 months as the company advances multiple base-editing programs, including risto-cel for sickle cell disease and BEAM-302 for alpha-1 antitrypsin deficiency.
Beam Therapeutics reported first quarter 2026 results alongside major clinical milestones. License and collaboration revenue rose to $31.7 million, up from $7.5 million a year earlier, while net loss narrowed to $94.3 million or $0.91 per share. Cash, cash equivalents and marketable securities totaled $1.2 billion as of March 31, 2026, supporting a projected cash runway into mid-2029.
Clinically, updated Phase 1/2 data for BEAM-302 in alpha-1 antitrypsin deficiency showed rapid, durable increases in total and functional AAT and a well‑tolerated safety profile, leading Beam to select 60 mg as the optimal biological dose and plan a pivotal expansion cohort in the second half of 2026 under an accelerated approval pathway. In sickle cell disease, Phase 1/2 BEACON data for risto-cel were published in The New England Journal of Medicine, and Beam expects to submit a biologics license application as early as year‑end 2026.
Beam also plans an IND filing for BEAM-304 in phenylketonuria and initial 2026 data for BEAM-301 in glycogen storage disease type Ia, while an ongoing healthy volunteer trial of BEAM-103 is expected to complete dosing in the first half of 2026.
Beam Therapeutics ownership filing shows Vanguard Capital Management reports beneficial ownership of 5,122,475 shares of common stock, representing 5.02% of the class. The filing states sole voting power for 745,101 shares and sole dispositive power for 5,122,475 shares; the report is dated 04/29/2026.
The disclosure notes holdings include securities held for various Vanguard affiliates and funds and follows SEC Release No. 34-39538 guidance on aggregated business-unit reporting.
Beam Therapeutics is asking stockholders to vote at a fully virtual 2026 annual meeting on June 3, 2026. The agenda includes electing three Class III directors (John Evans, John Maraganore, Ph.D., and Christi Shaw), ratifying Deloitte & Touche LLP as auditor for 2026, and approving NEO pay on an advisory basis.
Stockholders of record at the close of business on April 7, 2026, when 102,745,693 common shares were outstanding, may vote online, by phone, mail, or during the webcast. The proxy details board structure, independence, risk oversight, and an executive pay program focused on performance-based cash bonuses and equity awards. In 2025, CEO John Evans received total compensation of $5.8 million, with bonuses funded at 135% of target after positive clinical, financing, and pipeline milestones.
Beam Therapeutics Inc. CEO John M. Evans reported an automatic sale of 30,078 shares of common stock on April 1, 2026 at $24.58 per share. According to the disclosure, these shares were sold in a non-discretionary transaction solely to cover tax withholding obligations tied to previously granted restricted stock units under the company’s 2019 Equity Incentive Plan, pursuant to a Rule 10b5-1 trading plan adopted in May 2023. Following this transaction, Evans directly holds 1,047,205 shares and indirectly holds 103,000 shares through the John M. Evans, III 2018 Irrevocable Trust, which total includes 616 shares acquired under the company’s amended and restated 2019 Employee Stock Purchase Plan on March 31, 2026.
Beam Therapeutics Inc. Chief Medical Officer Amy Simon reported an open-market sale of 6,700 shares of common stock at $24.58 per share. According to the filing, these shares were automatically sold to cover tax withholding obligations tied to vesting of restricted stock units under Beam’s 2019 Equity Incentive Plan and were executed under a pre-arranged Rule 10b5-1 trading plan. After this transaction, Simon directly holds 102,735 Beam shares, and the total includes shares acquired through the company’s Employee Stock Purchase Plan.
Beam Therapeutics SVP Finance Bethany J. Cavanagh reported an automatic sale of common stock mainly to cover taxes on vesting equity awards. On April 1, 2026, 3,242 shares were sold in an open-market transaction at $24.58 per share. These shares were sold to satisfy tax withholding obligations tied to restricted stock units granted under the company’s 2019 Equity Incentive Plan that vested on multiple March 31 dates from 2022 through 2025. Following the sale, Cavanagh directly holds 51,171 Beam Therapeutics shares. The filing notes the transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 9, 2024, indicating the timing was set in advance rather than chosen opportunistically.
Beam Therapeutics Inc. Chief Legal Officer Christine Bellon reported an automatic sale of 5,956 shares of common stock on April 1, 2026 at $24.58 per share. After this transaction, she directly holds 109,711 shares of Beam Therapeutics common stock.
The shares were sold in a non-discretionary transaction solely to cover tax withholding obligations arising from the vesting of restricted stock units granted on March 31 of 2022, 2023, 2024 and 2025 under the company’s 2019 Equity Incentive Plan. The sales were effected under a Rule 10b5-1 trading plan adopted on May 19, 2023, indicating the trades were pre-planned rather than opportunistic market sales.